SEC Comment Letter 0000000000-24-001585 to REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH, RVPHW) (CIK 0001742927) (RVPH)

REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH, RVPHW) (CIK 0001742927)
Date: Feb. 9, 2024 · CIK: 0001742927 · Accession: 0000000000-24-001585

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-276848

Date

February 9, 2024

Author

Not clearly detected

Form

UPLOAD

Company

REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH, RVPHW) (CIK 0001742927)

Letter

United States securities and exchange commission logo February 9, 2024 Laxminarayan Bhat Chief Executive Officer Reviva Pharmaceuticals Holdings, Inc. 19925 Stevens Creek Blvd., Suite 100 Cupertino, CA, 95014 Re:Reviva Pharmaceuticals Holdings, Inc. Registration Statement on Form S-3 Filed February 2, 2024 File No. 333-276848 Dear Laxminarayan Bhat: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Lloyd Jeglikowski, Esq.

Show Raw Text

United States securities and exchange commission logo
February 9, 2024
Laxminarayan Bhat
Chief Executive Officer
Reviva Pharmaceuticals Holdings, Inc.
19925 Stevens Creek Blvd., Suite 100
Cupertino, CA, 95014
Re:Reviva Pharmaceuticals Holdings, Inc.
Registration Statement on Form S-3
Filed February 2, 2024
File No. 333-276848
Dear Laxminarayan Bhat:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Lloyd Jeglikowski, Esq.

SecProbe.io